Namrata Vijayvergia
Overview
Explore the profile of Namrata Vijayvergia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
743
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sridharan A, Dotan E, Dorta M, Vemula N, Handorf E, Deng M, et al.
J Gastrointest Cancer
. 2025 Feb;
56(1):67.
PMID: 39954184
Purpose: Five-year survival for pancreatic adenocarcinoma (PDAC) is < 10% but can vary by a patient's race, socioeconomic status (SES), and the factors related to the neighborhood where a patient...
2.
Vijayvergia N
Clin Adv Hematol Oncol
. 2024 Dec;
22 Suppl 8(10):5-15.
PMID: 39688625
No abstract available.
3.
Tan W, Cramer L, Vijayvergia N, Lustberg M, Kunz P
Ther Adv Med Oncol
. 2024 Dec;
16:17588359241292271.
PMID: 39687054
Background: Sex disparities are known modifiers of health and disease. In neuroendocrine neoplasms (NENs), sex-based differences have been observed in the epidemiology and treatment-related side effects. Objectives: To examine sex...
4.
Chan J, Geyer S, Zemla T, Knopp M, Behr S, Pulsipher S, et al.
N Engl J Med
. 2024 Sep;
392(7):653-665.
PMID: 39282913
Background: Treatment options for patients with advanced neuroendocrine tumors are limited. The efficacy of cabozantinib in the treatment of previously treated, progressive extrapancreatic or pancreatic neuroendocrine tumors is unclear. Methods:...
5.
Boland P, Mukherjee S, Imanirad I, Vijayvergia N, Cohen S, Gupta M, et al.
Br J Cancer
. 2024 Sep;
131(8):1290-1297.
PMID: 39244627
Background: The efficacy of FOLFIRI plus an antiangiogenesis biologic agent as 2nd line therapy for metastatic colorectal adenocarcinoma is limited. TAS-102 is a novel oral antimetabolite with a distinct mechanism...
6.
Cannon T, Rothe M, Mangat P, Garrett-Mayer E, Chiu V, Hwang J, et al.
J Clin Oncol
. 2024 May;
42(27):3228-3237.
PMID: 38748939
Purpose: Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations...
7.
Robbins J, Halegoua-DeMarzio D, Basu Mallick A, Vijayvergia N, Ganetzky R, Lavu H, et al.
N Engl J Med
. 2023 Nov;
389(21):1972-1978.
PMID: 37991855
Mahvash disease is an exceedingly rare genetic disorder of glucagon signaling characterized by hyperglucagonemia, hyperaminoacidemia, and pancreatic α-cell hyperplasia. Although there is no known definitive treatment, octreotide has been used...
8.
Del Rivero J, Perez K, Kennedy E, Mittra E, Vijayvergia N, Arshad J, et al.
J Clin Oncol
. 2023 Sep;
41(32):5049-5067.
PMID: 37774329
Purpose: To develop recommendations for systemic therapy for well-differentiated grade 1 (G1) to grade 3 (G3) metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Methods: ASCO convened an Expert Panel to conduct a...
9.
Kaur J, Vijayvergia N
Curr Oncol
. 2023 Sep;
30(9):8653-8664.
PMID: 37754542
Gastroentero-pancreatic Neuroendocrine Neoplasms (GEP-NENs) are a diverse group of rare tumors that arise from neuroendocrine cells in the gastrointestinal tract and pancreas, and they can vary significantly in terms of...
10.
Snyder R, Burtness B, Cho M, Del Rivero J, Doroshow D, Hitchcock K, et al.
J Natl Cancer Inst
. 2023 Jun;
115(10):1132-1138.
PMID: 37364007
Many multicenter randomized clinical trials in oncology are conducted through the National Clinical Trials Network (NCTN), an organization consisting of 5 cooperative groups. These groups are made up of multidisciplinary...